Literature DB >> 8690299

Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2.

T N Young1, G C Rodriguez, A R Rinehart, R C Bast, S V Pizzo, M S Stack.   

Abstract

Substantial evidence indicates that proteolytic degradation of the extracellular matrix is necessary for invasion and metastasis by cancer cells. Our previous work has demonstrated elevated secretion by cultured ovarian adenocarcinoma cells of two gelatinolytic metalloproteinases, a 72-kDa enzyme resembling matrix metalloproteinase 2 (MMP-2) and a 92-kDa enzyme resembling MMP-9 (Moser et al, Int. J. Cancer 56, 552-559, 1994). To assess the potential in vivo relevance of these enzymes, we have examined ovarian carcinoma ascites using gelatin substrate zymography. MMP species identical to those secreted from several well-characterized ovarian adenocarcinoma cell lines were found in the majority of ascites: MMP-2-like gelatinase (23 of 23 cases) and MMP-9-like gelatinase (18 of 23 cases), suggesting a prevalence of these species in the ovarian carcinoma microenvironment and their availability for tumor-associated proteolysis. The contribution of these proteinases to ovarian cancer invasion was further demonstrated by experiments measuring tumor cell-mediated proteolysis of native endothelial cell extracellular matrix (ECM) and tumor cell invasion of reconstituted basement membrane (Matrigel). These data showed that secretion of type IV collagenase activity by a series of independently isolated ovarian adenocarcinoma cell lines correlated well with the ability of these cells to proteolyze the ECM and invade the basement membrane. Furthermore, we have identified and characterized an ovarian carcinoma-associated gelatinase, the 72-kDa MMP found in conditioned media of the DOV 13 cell line, as MMP-2. This enzyme was identical to the previously described MMP-2 from other sources by Western blot, amino terminal sequence, and substrate specificity. Additionally, a large portion of the MMP-2 activity found in DOV 13 conditioned media is active without organomercurial treatment, suggesting that ovarian cancer cells have an endogenous activator of the zymogen. Together, these data suggest that ECM proteolysis mediated by tumor-associated proteinases plays an important role in the invasion and/or metastasis of ovarian carcinoma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8690299     DOI: 10.1006/gyno.1996.0195

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  19 in total

1.  Membrane type-1 matrix metalloproteinase (MT1-MMP) correlates with the expression and activation of matrix metalloproteinase-2 (MMP-2) in inflammatory breast cancer.

Authors:  Diaa Al-Raawi; Helal Abu-El-Zahab; Mohamed El-Shinawi; Mona Mostafa Mohamed
Journal:  Int J Clin Exp Med       Date:  2011-10-11

2.  Integrin regulation of beta-catenin signaling in ovarian carcinoma.

Authors:  Rebecca J Burkhalter; Jaime Symowicz; Laurie G Hudson; Cara J Gottardi; M Sharon Stack
Journal:  J Biol Chem       Date:  2011-04-25       Impact factor: 5.157

3.  TGFBI expression reduces in vitro and in vivo metastatic potential of lung and breast tumor cells.

Authors:  Gengyun Wen; Michael A Partridge; Bingyan Li; Mei Hong; Wupeng Liao; Simon K Cheng; Yongliang Zhao; Gloria M Calaf; Tian Liu; Jun Zhou; Zengli Zhang; Tom K Hei
Journal:  Cancer Lett       Date:  2011-05-10       Impact factor: 8.679

4.  Matrix-degrading proteinases are shed in membrane vesicles by ovarian cancer cells in vivo and in vitro.

Authors:  V Dolo; S D'Ascenzo; S Violini; L Pompucci; C Festuccia; A Ginestra; M L Vittorelli; S Canevari; A Pavan
Journal:  Clin Exp Metastasis       Date:  1999-03       Impact factor: 5.150

5.  High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma.

Authors:  B Davidson; I Goldberg; W H Gotlieb; J Kopolovic; G Ben-Baruch; J M Nesland; A Berner; M Bryne; R Reich
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

6.  Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer.

Authors:  Giuseppe Morgia; Mario Falsaperla; Grazia Malaponte; Massimo Madonia; Manuela Indelicato; Salvatore Travali; Maria Clorinda Mazzarino
Journal:  Urol Res       Date:  2004-10-22

Review 7.  Activated epidermal growth factor receptor in ovarian cancer.

Authors:  Laurie G Hudson; Reema Zeineldin; Melina Silberberg; M Sharon Stack
Journal:  Cancer Treat Res       Date:  2009

Review 8.  EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma.

Authors:  Laurie G Hudson; Natalie M Moss; M Sharon Stack
Journal:  Future Oncol       Date:  2009-04       Impact factor: 3.404

9.  Detection of type IV collagenase activity in malignant ascites.

Authors:  Xiao-Min Sun; Wei-Guo Dong; Bao-Ping Yu; He-Sheng Luo; Jie-Ping Yu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

Review 10.  Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression.

Authors:  Laurie G Hudson; Reema Zeineldin; M Sharon Stack
Journal:  Clin Exp Metastasis       Date:  2008-04-09       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.